TwoStep raises $62.5M Series A for its twist on cancer ADCs
What's the deal? TwoStep TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised a $62.5 million Series A to advance its cancer treatments toward the clinic. Pfizer VenturesDealroom has a profile for this one. Try Dealroom → and M VenturesDealroom has a profile for this one. Try Dealroom →, the venture arm of Merck KGaADealroom has a profile for this one. Try Dealroom →, backed the round.
What's the endgame? The startup is taking a different approach to antibody-drug conjugates (ADCs) and radioligands, two fast-growing fields in oncology. The new funding is aimed at moving its programme into clinical testing.
Why now? ADCs have become one of the most sought-after formats in cancer drug development, drawing heavy interest from large pharmaceutical companies. Backing from PfizerDealroom has a profile for this one. Try Dealroom → and Merck KGaA's venture groups signals appetite among big players for novel takes on the technology.
The signal: At $62.5 million, the round lands in the 95th percentile of all US health Series A rounds on record — a sample of 5,904 deals. That scale underscores how much capital investors are willing to commit to differentiated oncology platforms before they reach the clinic.
Read more: endpoints.news
Image credit: TwoStep Therapeutics
